Charles Explorer logo
🇬🇧

Nivolumab induced encephalopathy in a man with metastatic renal celll cancer: a case report

Publication at Faculty of Medicine in Hradec Králové |
2018

Abstract

Great progress has recently been made in the treatment of metastatic renal cell carcinoma, including the introduction of nivolumab, an immune checkpoint inhibitor. Despite promising results, this treatment brings a completely new spectrum of adverse events, distinct from those experienced with small-molecule kinase inhibitors.

The examination of cerebrospinal fluid for paraneoplastic antibodies, such as anti-N-methyl-D-aspartate receptor and anti-Ma2 antibodies, in order to distinguish autoimmune etiology from other possible causes is essential and highly recommended.